These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8900526)

  • 1. [Criteria for the use of tumor markers. 1: Quality assurance--characteristics of the most important tumor markers].
    Fateh-Moghadam A; Stieber P
    Fortschr Med; 1996 Feb; 114(6):30-3. PubMed ID: 8900526
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality assurance of predictive markers in breast cancer.
    Rhodes A; Barnes DM
    Methods Mol Med; 2004; 97():29-57. PubMed ID: 15064483
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular oncodiagnostics: where we are and where we need to go.
    Liu ET
    J Clin Oncol; 2003 Jun; 21(11):2052-5. PubMed ID: 12775728
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of predictive values of tumor markers.
    Roulston JE
    Methods Mol Med; 2004; 97():13-27. PubMed ID: 15064482
    [No Abstract]   [Full Text] [Related]  

  • 5. [Quality control in tumor marker values: methology, results and potential problems].
    Ben Ayed M; Ben Hadj Hmida Y; Kassis M; Damak J; Masmoudi H
    Tunis Med; 2001; 79(6-7):341-7. PubMed ID: 11771428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organ preservation in head and neck cancer: are there reliable molecular predictors?
    Hanna EY
    Curr Oncol Rep; 2001 Jan; 3(1):43-4. PubMed ID: 11123868
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tumor markers--how they should be applied].
    Stieber P; Heinemann V; Schalhorn A
    MMW Fortschr Med; 2005 May; 147(20):35, 37-9. PubMed ID: 15957858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor markers: theory or reality?].
    Molina R; Filella X; Ballesta AM
    Med Clin (Barc); 1994 Feb; 102(5):189-95. PubMed ID: 8127170
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usefulness of the tumor markers in the diagnosis of idiopathic deep venous thrombosis associated cancer].
    Enguídanos MJ; Todolí JA; Saro E; Salvador G; Villar J; Gómez-Biedma S; Micó L; Calabuig JR
    An Med Interna; 2002 Nov; 19(11):561-6. PubMed ID: 12522891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [How reliable are tumor markers? Only the experienced physician knows how to apply these diagnostic aids sensibly].
    Janssen K
    Fortschr Med; 1995 Feb; 113(4):49-51. PubMed ID: 7713468
    [No Abstract]   [Full Text] [Related]  

  • 12. Concomitant analysis of salivary tumor markers--a new diagnostic tool for oral cancer.
    Nagler R; Bahar G; Shpitzer T; Feinmesser R
    Clin Cancer Res; 2006 Jul; 12(13):3979-84. PubMed ID: 16818695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunohistochemistry Circle Trial of the University Institute of Pathology in Germany].
    Rüdiger T; Höfler H; Müller-Hermelink HK
    Pathologe; 1997 May; 18(3):262-8. PubMed ID: 9273547
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
    Sütterlin M; Bussen S; Trott S; Caffier H
    Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunohistochemical studies].
    Dietz A; Bosch F
    HNO; 2004 May; 52(5):468-70. PubMed ID: 15088091
    [No Abstract]   [Full Text] [Related]  

  • 16. Screening and monitoring for bladder cancer: refining the use of NMP22.
    Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD
    J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer.
    Schmitt M; Harbeck N; Daidone MG; Brynner N; Duffy MJ; Foekens JA; Sweep FC
    Int J Oncol; 2004 Nov; 25(5):1397-406. PubMed ID: 15492831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
    Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
    Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
    Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
    Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Legal (liability) aspects of PSA determination].
    Mielke K
    Urologe A; 2006 Jun; 45(6):756-65. PubMed ID: 16788794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.